Plus, news about Vyne Therapeutics, Aclaris Therapeutics, Dx&Vx, Larimar Therapeutics, Incannex and Poxel:
Merck stops work on two programs: The drugmaker plans to discontinue MK-6194, which it was testing in Phase 2 trials in vitiligo ...
↧